Clinical Importance of Pulse Wave Velocity

Artery stiffness is an independent predictor of cardiovascular events in patients with hypertension.1

Aortic stiffness is a determinant of isolated systolic hypertension.2

Measuring and monitoring arterial stiffness may improve cardiovascular risk determination.3

SphygmoCor PWV - the Gold Standard

Carotid-femoral pulse wave velocity has demonstrated the ability to predict cardiovascular events independent of traditional risk factors in a diverse population. 4-7 The 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines for the management of hypertension identify cfPWV as a marker of target organ damage and a predictor of CV risk. 8 The SphygmoCor XCEL cfPWV has been validated per the ARTERY PWV validation guidelines.

SphygmoCor XCEL PWV Software

The SphygmoCor XCEL PWV software provides the clinician or researcher with a personalized patient visit report displaying the femoral and carotid arterial pulses recorded during the measurement, heart rate, pulse wave velocity, as well as pulse wave transit time.  Measurements are compliant with HIPAA and GDPR. 

Optional data and training services are available:

  • Certification of clinician and researcher PWV assessments
  • Data quality overread services and QC checks
  • Full data extraction for integration and statistical analysis

Comprehensive Assessments Using PWA and PWV

The SphygmoCor XCEL may be configured to perform Pulse Wave Analysis (PWA) in addition to PWV assessments, providing a complete assessment of a patient’s vascular health, clinical impacts during interventional trials, and patient-centric therapeutic treatments.

Full reporting allows for the waveform (shown to the left) and biomarkers to be tracked longitudinally to identify and provide appropriate patient care based on changes in vascular health with age.

Citations and References

  1. Laurent 2 et al., Hypertension 2001; 37:1236-1241 and. Reference: Vlachopoulos C et al., J Am Coll Cardiol 2010; 55:1318-1327.
  2. Safar ME et al., Circulation 2003; 107:2864-2869.
  3. Sehestedt T et al., Eur Heart J 2010; 31:883-891. Reference: Mattace-Raso FU et al., Circulation 2006; 113:657-663. Reference: Mitchell GF et al., Circulation 2010; 121:505-511.
  4. Hashimoto J. Tohoku J Exp Med 2014;233:1-8.
  5. O’Rourke et al. Br J Clin Pharmacol 2001;51:507-22.
  6. Sharman JE et al. J Hum Hypertens 2008; Dec 22(12):838-844.
  7. McEniery et al. Hypertension 2008; 6(51):1476-1482.
  8. Mancia et al. Hypertension 2013, 31:1281-1357.
  9. Wilkinson IB, et al. Artery Res 2010;4:34-40.

Over 30 Years of Technology Leadership and Partnerships

ATCOR’s digital vascular biomarkers benefit patients everywhere.